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1Cangrelor is a rapidly acting, potent, reversible intravenous platelet P2Y12 adenosine diphosphate receptor antago-
nist that recently received approval by the Food and Drug 
Administration for use in patients undergoing percutaneous 
coronary intervention (PCI).1 Cangrelor significantly reduced 
48-hour ischemic complications, including stent thrombo-
sis (ST), during PCI without a significant excess in severe 
bleeding compared with clopidogrel in the Cangrelor Versus 
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Standard Therapy to Achieve Optimal Management of Platelet 
Inhibition (CHAMPION) PHOENIX trial.2,3 These primary 
results were consistently demonstrated across major sub-
groups. Despite the lack of any significant interaction in the 
prespecified treatment-by-region analyses, an in-depth char-
acterization of the geographic variation in clinical profiles and 
outcomes in this global, contemporary PCI trial is worthwhile. 
Indeed, differences in event rates between countries have been 
estimated in some cardiovascular trials to be larger than the 
observed treatment effects of the study intervention.4,5
CHAMPION PHOENIX enrolled 11 145 patients from 
153 global sites from 12 different countries, with almost 40% 
of patients enrolled from the United States.2 In spite of applica-
tion of strict inclusion and exclusion criteria, some variability 
in the patients enrolled in each geographic region is expected, 
as observed in recent large antiplatelet trial programs.6,7 
Geographic heterogeneity in trial outcomes may have impor-
tant implications in regional approval by regulatory bodies. In 
this prespecified subgroup analysis, we describe the baseline 
characteristics, safety and efficacy end points, and response 
to cangrelor in patients enrolled in US and non-US sites in 
CHAMPION PHOENIX.
Methods
Study Population
The study design,8 protocol,9 and primary results2 of CHAMPION 
PHOENIX have been described previously. In brief, CHAMPION 
PHOENIX was an international, prospective, double-blind, double-
dummy, active-controlled trial designed to examine the periproce-
dural safety and efficacy of cangrelor compared with oral clopidogrel 
administered at the time of PCI. Patients ≥18 years of age requir-
ing PCI for stable angina, non–ST-segment–elevation acute coronary 
syndromes, or ST-segment–elevation myocardial infarction (MI) 
were eligible for enrollment. Patients were excluded if they received 
a P2Y12 antagonist or abciximab within 7 days of randomization or a 
glycoprotein IIb/IIIa inhibitor or fibrinolytic therapy within 12 hours 
of randomization. The protocol was approved by the institutional re-
view boards or ethics committees at each participating center, and 
written informed consent was obtained from all enrolled patients.
Study Treatment
Cangrelor or matching placebo was given as a bolus (30 μg/kg) and 
infusion (4 μg/kg per minute) during PCI and for 2–4 hours after-
ward. A clopidogrel loading dose (600 or 300 mg, at the discretion 
of the operator) or matching placebo was given at the time of PCI. 
Approximately 2 hours after PCI, the infusion (cangrelor or placebo) 
was discontinued and then patients received clopidogrel 600 mg (in 
the cangrelor arm) or matching placebo (in the clopidogrel arm). All 
patients received aspirin (75–325 mg). Clopidogrel 75 mg was ad-
ministered during the first 48 hours, after which P2Y12 inhibition was 
left to the discretion of the site investigator. Similarly, selection of ac-
cess site, stent type, sheath management protocol, and periprocedural 
anticoagulation were determined by local site investigators. Rescue 
glycoprotein IIb/IIIa inhibitors were reserved for management of 
periprocedural thrombotic complications.
Study End Points
This prespecified subgroup analysis9 evaluated the same safety 
and efficacy end points as the main CHAMPION PHOENIX tri-
al. Consistent with the overall CHAMPION PHOENIX analytic 
scheme, efficacy end points were assessed in the modified intention-
to-treat population, which included all patients who underwent PCI 
and received study drug. The safety end points were assessed in pa-
tients who underwent randomization and received at least one dose 
of the study drug. The primary efficacy end point was the composite 
rate of all-cause mortality, MI, ischemia-driven revascularization, 
or ST at 48 hours after randomization. The key secondary efficacy 
end point was the incidence of ST at 48 hours, which included both 
Academic Research Consortium–defined ST10 and intraprocedural 
ST (defined as new or worsened stent-related thrombus as assessed 
by frame-by-frame analysis by a blinded angiographic core labora-
tory [Cardiovascular Research Foundation, New York City, NY]).3 
MI was defined according to the second universal definition.11 
Secondary efficacy events occurring at 30 days postrandomization, 
including death, MI, ischemia-driven revascularization, or ST, were 
all specifically adjudicated by an independent and blinded Clinical 
Events Committee (Duke Clinical Research Institute, Durham, 
NC). The primary safety end point was noncoronary artery bypass 
graft–related severe/life-threatening bleeding, according to Global 
Use of Strategies to Open Occluded Arteries (GUSTO) criteria at 
48 hours. Requirement for transfusion and other bleeding indices 
including Thrombolysis in Myocardial Infarction (TIMI) and Acute 
Catheterization and Urgent Intervention Triage Strategy (ACUITY) 
were also assessed.
Statistical Analysis
All primary and secondary analyses detailed in the main trial publi-
cation2 were repeated separately in the US versus the non-US sub-
groups, as designated by the original trial protocol.9 Efficacy and 
safety end points were compared between geographic regions and 
between cangrelor and clopidogrel arms within each individual re-
gion. Logistic regression analyses were used to estimate effect sizes, 
expressed as odds ratios (OR) and 95% confidence intervals (CI). To 
account for minor discrepancies in clinical profiles between treatment 
arms in US and non-US subsets, multiple logistic regression models 
were adjusted for covariates which differed between treatment arms 
WHAT IS KNOWN
•	Cangrelor is a rapidly acting, potent, reversible intra-
venous platelet P2Y12 receptor antagonist.
•	Cangrelor Versus Standard Therapy to Achieve 
Optimal Management of Platelet Inhibition 
(CHAMPION) PHOENIX was a global, phase III 
randomized controlled trial, which formed the basis 
of cangrelor’s approval for use in patients undergo-
ing percutaneous coronary intervention.
WHAT THE STUDY ADDS
•	Despite substantial international variation in clini-
cal profiles and indications for percutaneous coro-
nary intervention by region, cangrelor consistently 
reduced rates of 48-hour ischemic complications 
during percutaneous coronary intervention without a 
significant excess in severe bleeding compared with 
clopidogrel in both the US and non-US subgroups of 
the CHAMPION PHOENIX trial.
•	Approximately 40% of patients included in 
CHAMPION PHOENIX were enrolled from the 
United States at an enrollment rate that was compa-
rable to non-US sites.
•	 In an era of decreasing US research engagement, ro-
bust US site participation in a global percutaneous 
coronary intervention trial was feasible with compa-
rable regional results.
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(P<0.15) in either regional subset. Treatment-by-region interaction 
analyses for each of the safety and efficacy end points were tested 
using the Breslow–Day method. Enrollment rates per country and re-
gion were calculated and expressed as number of patients per site per 
month with enrollment duration estimated from study start and end 
dates. Continuous variables are presented as mean±standard devia-
tion (SD) or as median (interquartile range [Q1, Q3]) and compared 
using Student’s t tests or Wilcoxon rank-sum tests, as appropriate. 
Categorical variables are presented as n (%) and compared using chi-
squared testing or Fisher’s exact tests, as appropriate. Kaplan–Meier 
curves by region were constructed for the primary efficacy and safety 
end points and key secondary end point and compared using log-rank 
tests. No adjustments were made for multiple comparisons. All statis-
tical analyses were performed using SAS software, version 9.3 (SAS 
Institute, Cary, NC).
Results
From September 30, 2010 to October 3, 2012, CHAMPION 
PHOENIX randomized 11 145 patients enrolled from 153 
global sites from 12 countries (Austria, Brazil, Bulgaria, 
Czech Republic, Georgia, Germany, Italy, New Zealand, 
Poland, Russia, Thailand, and the United States). The number 
of enrolled subjects and sites per country varied (Figure 1). 
The United States enrolled the highest number of patients 
(n=4188; 37.6%) from 63 enrolling sites. Of this randomized 
cohort, 10 942 patients (98.2%) ultimately underwent PCI and 
received the assigned drug and were included in the intention-
to-treat analysis. Follow-up was available at 48 hours and 30 
days in 10 939 and 10 919 patients, respectively. The final ana-
lytic cohort was based on the intention-to-treat trial popula-
tion, and the present analysis compared the clinical profiles of 
patients enrolled from the US (n=4097; 37.4%) versus non-
US sites (n=6845; 62.6%).
Baseline Characteristics
Baseline characteristics were well-balanced between cangre-
lor and clopidogrel arms within each region (Table I in the 
Data Supplement). However, distinct differences in demo-
graphic, clinical, and angiographic characteristics were 
observed in almost every variable between US and non-US 
regions (Table 1). The US cohort was older and more likely 
to be female (P<0.001 for both). Over 90% of CHAMPION 
PHOENIX participants were white, regardless of region, but 
the US group had higher rates of black and Hispanic/Latino 
participation (P<0.001). US patients consistently had higher 
rates of comorbid diseases (including diabetes mellitus, 
hypertension, hyperlipidemia, peripheral artery disease, heart 
failure), prior PCI or coronary artery bypass graft, and family 
history of coronary artery disease (all comparisons, P<0.001). 
Stable angina was more frequently the indication for PCI in 
US compared with non-US patients (77.9% versus 46.2%), 
whereas non–ST-segment–elevation acute coronary syn-
dromes (19.2% versus 30.8%) and ST-segment–elevation MI 
(2.9% versus 23.0%) were more common indications outside 
the United States (P<0.001). Cardiac biomarkers were abnor-
mal at baseline in 45.2% in the non-US subgroup compared 
with 21.7% in the US subgroup (P<0.001). Regional variation 
was also observed in periprocedural medication administra-
tion. Almost all US patients (99.1%) were intended to receive 
clopidogrel loading doses of 600 mg, whereas 40.5% of non-
US patients were intended to receive 300 mg (P<0.001). 
Bivalirudin was more frequently used in US patients (56.7% 
versus 2.9%), whereas other anticoagulants were used more 
frequently in non-US patients (all comparisons, P<0.001). 
Radial access (29.8% versus 23.9%) and drug-eluting stents 
(68.8% versus 47.7%) were used at higher rates in the US 
cohort versus non-US cohort (P<0.001 for both).
Regional Enrollment Rates
Enrollment rates did not differ substantially between US sites 
(2.7 patients/site per month) and non-US sites (3.2 patients/
site per month). However, enrollment rates ranged markedly 
across countries from 0.5 patients/site per month in New Zea-
land to 12.1 patients/site per month in Georgia.
Primary Efficacy End Point
The main outcomes are displayed by region and treatment 
assignment in Table 2. A total of 224 patients (5.5%) in the 
US cohort and 355 patients (5.2%) in the non-US cohort 
experienced the primary composite efficacy end point of 
death from any cause, MI, ischemia-driven revascularization, 
or ST at 48 hours (P=0.53). Rates of the primary composite 
end point were lower in the cangrelor arm compared with the 
clopidogrel arm in US (4.5% versus 6.4%; OR 0.70 [95% CI 
0.53–0.92]) and non-US patients (4.8% versus 5.6%; OR 0.85 
[95% CI 0.69–1.05]); interaction P=0.26. Multiple logistic 
regression analyses accounted for age, body weight, cardiac 
biomarker status, current smoking status, prior MI, previous 
coronary artery bypass graft, and history of peripheral artery 
disease. Even after accounting for the minimal observed varia-
tion between treatment arms in regional subgroups, cangrelor 
consistently reduced the primary end point compared with 
clopidogrel in US (adjusted OR 0.69 [95% CI 0.52–0.91]) 
and non-US subsets (adjusted OR 0.82 [95% CI 0.66–1.03]); 
adjusted interaction P=0.34. Figure I in the Data Supplement 
displays comparative unadjusted OR estimates for each indi-
vidual country. Kaplan–Meier estimates of the time-to-primary 
end point are shown in the US (Figure 2A) and non-US sub-
groups (Figure 2B).
Stent Thrombosis
Similarly, 36 patients (0.9%) in the United States and 84 
patients (1.2%) outside the United States experienced ST at 
Figure 1. Number of enrolled patients (black bars) and sites (gray 
bars) per country in the Cangrelor Versus Standard Therapy to 
Achieve Optimal Management of Platelet Inhibition (CHAMPION) 
PHOENIX trial.
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Table 1. Baseline Characteristics in US and Non-US Subgroups
Characteristics US (N=4097) Non-US (N=6845) P Value
Age, y
  Mean±SD (N) 64.40±11.02 (4097) 63.62±10.94 (6845) <0.001
  Median (Q1, Q3) 65.00 (57.00, 72.00) 64.00 (56.00, 72.00)
  Range (Min, Max) (26.00, 95.00) (26.00, 94.00)
Female 30.12% (1234/4097) 26.54% (1817/6845) <0.001
Race* <0.001
  White 91.67% (3753/4094) 95.04% (6499/6838)
  Asian 0.88% (36/4094) 4.53% (310/6838)
  Black 6.64% (272/4094) 0.34% (23/6838)
  Other 0.81% (33/4094) 0.09% (6/6838)
Hispanic or Latino 4.32% (177/4097) 3.10% (212/6845) <0.001
Weight
  Mean±SD (N) 89.73±19.94 (4097) 82.82±15.90 (6845) <0.001
  Median (Q1, Q3) 88.20 (76.50, 101.70) 82.00 (72.00, 92.00)
  Range (Min, Max) (35.20, 223.00) (30.00, 186.00)
Diagnosis at presentation <0.001
  Stable angina 77.94% (3193/4097) 46.24% (3165/6845)
  NSTE-ACS 19.16% (785/4097) 30.78% (2107/6845)
  STEMI 2.90% (119/4097) 22.98% (1573/6845)
Cardiac biomarker status† <0.001
  Normal 78.26% (3203/4093) 54.81% (3749/6840)
  Abnormal 21.74% (890/4093) 45.19% (3091/6840)
Medical history
  Diabetes mellitus 33.44% (1367/4088) 24.68% (1688/6839) <0.001
  Current smoker 24.52% (982/4005) 31.04% (2071/6673) <0.001
  Hypertension 82.49% (3374/4090) 78.15% (5332/6823) <0.001
  Hyperlipidemia 79.50% (3211/4039) 61.79% (3490/5648) <0.001
  Stroke or TIA 4.57% (187/4088) 4.81% (328/6819) 0.57
  Myocardial infarction 18.57% (752/4049) 22.20% (1515/6823) <0.001
  PCI 33.62% (1374/4087) 17.95% (1227/6836) <0.001
  CABG 16.50% (675/4091) 5.89% (403/6839) <0.001
  Congestive heart failure 12.51% (511/4084) 9.15% (625/6832) <0.001
  Peripheral artery disease 10.48% (426/4064) 6.00% (406/6762) <0.001
Family history of CAD 61.17% (2371/3876) 28.24% (1796/6359) <0.001
Periprocedural medications
  Clopidogrel, 300 mg loading dose‡ 0.90% (37/4097) 40.45% (2769/6845) <0.001
  Clopidogrel, 600 mg loading dose‡ 99.10% (4060/4097) 59.55% (4076/6845) <0.001
  Bivalirudin 56.67% (2321/4096) 2.92% (200/6844) <0.001
  UFH 56.64% (2320/4096) 90.99% (6228/6845) <0.001
  LMWH 11.62% (476/4097) 14.74% (1009/6843) <0.001
  Fondaparinux 0.17% (7/4097) 4.15% (284/6844) <0.001
  Aspirin 91.54% (3745/4091) 95.97% (6567/6843) <0.001
(Continued )
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48 hours (P=0.09). Cangrelor reduced rates of ST in patients 
enrolled in the United States (0.5% versus 1.3%; OR 0.38 
[95% CI 0.18–0.79]) and outside the United States (1.1% ver-
sus 1.4%; OR 0.75 [95% CI 0.48–1.15]); interaction P=0.12 
(Figure II in the Data Supplement).
Other Efficacy End Points
MI was the most frequent efficacy outcome and accounted 
for 85.7% and 76.1% of the primary composite events in 
the US and non-US cohorts, respectively. Cangrelor signifi-
cantly reduced risk of MI in US patients (3.7% versus 5.7%; 
P=0.002), but not in non-US patients (3.9% versus 4.0%; 
P=0.71) compared with clopidogrel (interaction P=0.03). This 
geographic heterogeneity of treatment effect on MI extended 
to 30 days (Table II in the Data Supplement). All-cause mor-
tality rates at 48 hours were low with very few events world-
wide (0.1% in US patients and 0.5% in non-US patients). The 
need for rescue glycoprotein IIb/IIIa inhibitors was lower in 
patients assigned to cangrelor compared with clopidogrel in 
both regions. Other secondary efficacy end points by region 
and treatment assignment are described in detail in Table II in 
the Data Supplement.
Safety End Points
The rates of the primary safety end point, GUSTO-defined 
severe/life-threatening bleeding, were low in both US (0.15%) 
and non-US regions (0.13%; Table 2). There was no significant 
treatment heterogeneity in cangrelor effect between regions in 
the primary safety end point (Figure III in the Data Supple-
ment), TIMI-defined bleeding, ACUITY-defined bleeding, or 
the need for blood transfusions.
In post hoc analysis, the primary efficacy and safety end 
points were combined to provide a composite end point of 
net adverse clinical events, which was reduced in the US by 
cangrelor (5.1% versus 6.8%) and in non-US regions (5.3% 
versus 5.9%); interaction P=0.26.
   ≤100 mg 36.54% (1330/3640) 68.11% (4058/5958) <0.001
   >100 mg 63.46% (2310/3640) 31.89% (1900/5958) <0.001
Catheter access site <0.001
  Femoral 70.03% (2869/4097) 75.89% (5195/6845)
  Radial 29.83% (1222/4097) 23.86% (1633/6845)
  Brachial 0.15% (6/4097) 0.25% (17/6845)
Number of vessels treated, index PCI <0.001
  0 0.00% (0/4043) 0.00% (0/6801)
  1 82.27% (3326/4043) 85.62% (5823/6801)
  2 16.35% (661/4043) 12.20% (830/6801)
  3 1.39% (56/4043) 2.00% (136/6801)
  4 0.00% (0/4043) 0.18% (12/6801)
Time from hospital admission to PCI, 
h, median (Q1, Q3)
3.40 (0.00, 9.00) 5.40 (2.00, 25.00) <0.001
Duration of PCI, min
  Mean±SD (N) 22.87±21.32 (4097) 22.45±18.25 (6843) 0.02
  Median (Q1, Q3) 17.00 (9.00, 29.00) 18.00 (10.00, 30.00)
  Range (Min, Max) (0.00, 359.00) (1.00, 227.00)
Drug-eluting stent 68.78% (2818/4097) 47.67% (3263/6845) <0.001
Bare metal stent 28.85% (1182/4097) 50.69% (3470/6845) <0.001
Balloon angioplasty 5.61% (230/4097) 4.89% (335/6845) 0.10
Values are n (%) or n/N (%). Baseline characteristics describe patients included in the modified intention-to-treat cohort. 
Denominators exclude patients in whom the status was reported as unknown by the study center. CABG indicates coronary 
artery bypass graft (surgery); CAD, coronary artery disease; LMWH, low molecular weight heparin; NSTE-ACS, non–ST-segment–
elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction; 
TIA, transient ischemic attack; and UFH, unfractionated heparin.
*Race was self-reported.
†Cardiac biomarker status was considered to be abnormal if at least 1 of the baseline troponin I or T levels, obtained within 
72 hours before randomization or after randomization but before initiation of the study drug, was greater than the upper limit of 
the normal range, as determined by the local laboratory. If the baseline troponin level was not available, the baseline myocardial 
band fraction of creatine kinase was used.
‡Percentage of patients receiving each clopidogrel loading dose is based on the planned or intended use declared at the time 
of stratification.
Table 1. Continued
Characteristics US (N=4097) Non-US (N=6845) P Value
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Table 2. Efficacy and Safety End Points at 48 h After Randomization in US and Non-US Subgroups
End Point
US (N=4097) Non-US (N=6845)
P, Regional 
Difference
P, Treatment- 
by-Region 
InteractionCangrelor Clopidogrel OR (95% CI) Cangrelor Clopidogrel OR (95% CI)
Efficacy N=2048 N=2049 N=3424 N=3421
  Primary end point: 
Death/MI/IDR/ST
93/2048 (4.5) 131/2049 (6.4) 0.70 (0.53, 0.92) 164/3422 (4.8) 191/3420 (5.6) 0.85 (0.69, 1.05) 0.53 0.26
  Key secondary 
end point: ST
10/2048 (0.5) 26/2049 (1.3) 0.38 (0.18, 0.79) 36/3422 (1.1) 48/3420 (1.4) 0.75 (0.48, 1.15) 0.09 0.12
  MI 75/2048 (3.7) 117/2049 (5.7) 0.63 (0.47, 0.84) 132/3422 (3.9) 138/3420 (4.0) 0.95 (0.75, 1.22) 0.06 0.03
  Q-wave MI 3/2048 (0.1) 7/2049 (0.3) 0.43 (0.11, 1.66) 8/3422 (0.2) 11/3420 (0.3) 0.73 (0.29, 1.81) 0.74 0.52
  IDR 12/2048 (0.6) 19/2049 (0.9) 0.63 (0.30, 1.30) 16/3422 (0.5) 19/3420 (0.6) 0.84 (0.43, 1.64) 0.11 0.56
  Death from any 
cause
5/2048 (0.2) 0/2049 (0.0) … 13/3422 (0.4) 18/3420 (0.5) 0.72 (0.35, 1.47) 0.003 0.02
  Death from 
cardiovascular 
causes
5/2048 (0.2) 0/2049 (0.0) … 13/3422 (0.4) 18/3420 (0.5) 0.72 (0.35, 1.47) 0.003 0.02
  Death/Q-wave 
MI/IDR
17/2048 (0.8) 22/2049 (1.1) 0.77 (0.41, 1.46) 32/3422 (0.9) 42/3420 (1.2) 0.76 (0.48, 1.21) 0.52 0.97
  Death/ST 15/2048 (0.7) 26/2049 (1.3) 0.57 (0.30, 1.09) 44/3422 (1.3) 61/3420 (1.8) 0.72 (0.49, 1.06) 0.02 0.56
Safety: non-CABG-
related bleeding
N=2062 N=2062 N=3467 N=3465
  GUSTO-defined 
bleeding
66/2062 (3.2) 43/2062 (2.1) 1.55 (1.05, 2.29) 112/3467 (3.2) 64/3465 (1.8) 1.77 (1.30, 2.42) 0.74 0.60
   Primary safety 
end point: 
Severe/life-
threatening
3/2062 (0.1) 3/2062 (0.1) 1.00 (0.20, 4.96) 6/3467 (0.2) 3/3465 (0.1) 2.00 (0.50, 8.01) 0.83 0.52
   Moderate 9/2062 (0.4) 6/2062 (0.3) 1.50 (0.53, 4.23) 13/3467 (0.4) 7/3465 (0.2) 1.86 (0.74, 4.67) 0.50 0.76
   Severe or 
moderate
12/2062 (0.6) 9/2062 (0.4) 1.34 (0.56, 3.18) 19/3467 (0.5) 10/3465(0.3) 1.90 (0.88, 4.10) 0.49 0.55
   Mild 54/2062 (2.6) 34/2062 (1.7) 1.60 (1.04, 2.47) 96/3467 (2.8) 54/3465 (1.6) 1.80 (1.23, 2.52) 0.92 0.68
  TIMI-defined 
bleeding
5/2062 (0.2) 4/2062 (0.2) 1.25 (0.34, 4.66) 9/3467 (0.3) 4/3465 (0.1) 2.25 (0.69, 7.32) 0.73 0.51
   Major 2/2062 (0.1) 3/2062 (0.1) 0.67 (0.11, 3.99) 3/3467 (0.1) 2/3465 (0.1) 1.50 (0.25, 8.98) 0.41 0.53
   Minor 3/2062 (0.1) 1/2062 (0.0) 3.00 (0.31, 28.89) 6/3467 (0.2) 2/3465(0.1) 3.00 (0.61, 14.88) 0.78 1.00
  ACUITY-defined 
bleeding
433/2062 (21.0) 300/2062 (14.5) 1.56 (1.33, 1.84) 423/3467 (12.2) 301/3465 (8.7) 1.46 (1.25, 1.71) <0.001 0.56
   Major 42/2062 (2.0) 29/2062 (1.4) 1.46 (0.90, 2.35) 193/3467 (5.6) 110/3465 (3.2) 1.80 (1.42, 2.28) <0.001 0.44
   Minor 394/2062 (19.1) 275/2062 (13.3) 1.53 (1.30, 1.82) 259/3467 (7.5) 200/3465 (5.8) 1.32 (1.09, 1.60) <0.001 0.24
  Any blood 
transfusion
9/2062 (0.4) 8/2062 (0.4) 1.13 (0.43, 2.92) 16/3467 (0.5) 8/3465 (0.2) 2.00 (0.86, 4.69) 0.58 0.37
Efficacy and safety: 
net adverse clinical 
events*
N=2048 N=2049 N=3424 N=3421
  Death/MI/IDR/ST/
GUSTO-defined 
moderate or 
severe bleeding
104/2048 (5.1) 139/2049 (6.8) 0.74 (0.57, 0.96) 180/3422 (5.3) 201/3420 (5.9) 0.89 (0.72,1.09) 0.43 0.26
Figures are expressed as number/total number (rate). The efficacy end points were assessed in patients included in the modified intention-to-treat population (which 
comprised patients who underwent percutaneous coronary intervention and received the study drug). The safety end points were assessed in patients who underwent 
randomization and received at least one dose of the study drug. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CABG, coronary 
artery bypass graft (surgery); CI, confidence interval; GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries; IDR, ischemia-driven revascularization; MI, 
myocardial infarction; OR, odds ratio; ST, stent thrombosis; and TIMI, Thrombolysis in Myocardial Infarction.
*The primary efficacy and primary safety end points were combined to provide a composite end point of net adverse clinical events in the modified intention-to-treat 
population.
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Discussion
Consistent with the overall CHAMPION PHOENIX results, 
this prespecified analysis confirmed relative homogeneity in 
the primary efficacy and safety end points for cangrelor versus 
clopidogrel in US and non-US subsets undergoing elective or 
urgent PCI. Furthermore, cangrelor consistently reduced net 
adverse clinical events (the composite of the primary efficacy 
and safety end points) compared with clopidogrel, regardless 
of geographic region. Challenges in site-based enrollment, 
economic pressures to complete trial protocols on shorter 
timelines, and improvements in background drug and device 
therapies have driven recent patterns of globalization of cardio-
vascular clinical trials.12 These secular trends have presented 
unique challenges and opportunities to dissect differential 
treatment responses by region in large global cardiovascular 
clinical trials. Unfortunately, fewer US sites are participating 
in emerging cardiovascular mega-trials. For instance, only 8% 
of all randomized patients in the Platelet Inhibition and Patient 
Outcomes (PLATO) trial were enrolled from US sites.6
In the context of declining US clinical trial participa-
tion, US share in global research funding,13 and US growth 
in Food and Drug Administration–regulated investigators,14 
CHAMPION PHOENIX clarifies that US engagement in 
global clinical trials in PCI is feasible. US sites enrolled 
the highest proportion (38%) of randomized patients in 
CHAMPION PHOENIX from only 63 sites. Furthermore, 
efficiency of enrollment was preserved with comparable 
enrollment rates across global regions. Site-based enrollment 
Figure 2. Kaplan–Meier failure curves for the primary efficacy end point in US (A) and non-US (B) subgroups. The primary efficacy end 
point of composite of death from any cause, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours 
after randomization was reduced by cangrelor in both US and non-US subgroups (interaction P=0.26) compared with clopidogrel in the 
modified intention-to-treat population (which comprised patients who underwent percutaneous coronary intervention and received the 
study drug). Failure functions were compared by region using the log-rank test.
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practices may shape patterns of patient profiles, protocol 
completion, and trial outcomes, potentially related to varia-
tion in the stringency of application of inclusion and exclusion 
criteria. In the Efficacy of Vasopressin Antagonism in Heart 
Failure: Outcome Study with Tolvaptan (EVEREST) trial, 
participants enrolled from low-enrolling sites were indepen-
dently at higher risk for adverse events.5,15 It is thus reassur-
ing that US sites in CHAMPION PHOENIX enrolled a high 
volume of patients expeditiously comparable to non-US sites 
(≈3 patients per site per month). This also suggests that the 
CHAMPION PHOENIX protocol fit nicely into contempo-
rary US practice at many sites.
Regional consistency of primary safety and efficacy end 
points in CHAMPION PHOENIX may be potentially related 
to several factors. First, despite wide differences in clinical 
profiles and PCI indications, overall event rates in US and 
non-US cohorts were similar. This international event burden 
may reflect standardization of global cardiovascular practices, 
guidelines, and background therapies. Rates of postprocedural 
MI have been reported to be higher in US compared with non-
US sites in certain experiences,16,17 but may have been offset 
in CHAMPION PHOENIX because of differential case mix, 
with a greater proportion of nonelective PCI performed in 
non-US sites. Second, all enrolling sites were PCI-capable 
and thus may possess certain unifying characteristics. Third, 
specific adjudication of end points by an independent Clinical 
Events Committee and a blinded angiographic core laboratory 
may minimize regional variability in end point assessment 
and treatment effects. Finally, its predictable pharmacologi-
cal profile, near-complete antiplatelet inhibition, and excel-
lent bioavailability may have contributed to the consistency 
of cangrelor’s actions across various populations of patients.18
Minimal heterogeneity is expected around the overall trial 
point estimate, especially in PCI trials, given systematic dif-
ferences in indications for PCI and concomitant treatment 
strategies (left to the discretion of local site investigators). The 
overall interaction terms were not significant for the primary 
and secondary efficacy end points, and the directionality of 
effects (favoring cangrelor) were preserved across regions; 
as such, the effect sizes and specific point estimates within 
each regional subset should be regarded with caution. Point 
estimates for the primary efficacy end point varied substan-
tially by country of enrollment and country-specific sample 
size, highlighting that small regional experiences may provide 
unstable estimates. Geographic variation in secondary treat-
ment outcomes may arise from variability in patient-related 
factors, regional medical practice, and end point assessment.19 
Despite adherence to strict criteria of enrollment, patients 
enrolled from different regions may vary in important ways, 
which may in turn influence treatment risk–benefit ratios, side 
effect profiles, and adherence patterns. US participants in 
CHAMPION PHOENIX had higher rates of established car-
diovascular disease and cardiovascular risk factors, and over 
70% underwent PCI for stable angina. In contrast with the 
findings related to the primary safety and efficacy end points, 
the risk reduction of periprocedural MI by cangrelor appeared 
to be confined to the US subgroup, which may be explained by 
several potential factors. Despite the use of the standardized, 
universal definition of post-PCI MI (type 4a)11 that leveraged 
adjunctive evidence of ischemia based on symptom reporting, 
angiography, and electrocardiography and an independent 
angiographic core laboratory for ST (type 4b),3,10 higher rates 
of PCI for acute coronary syndrome in non-US participants 
may have confounded the detection of periprocedural MI. 
Historically, nonfatal ischemic end points, such as MI, have 
been subject to underreporting and potentially greater regional 
influence. In CHAMPION PHOENIX, however, post-PCI 
biomarkers were collected per protocol and processed in core 
laboratories for almost all adjudicated MIs. Processing of bio-
marker samples in local laboratories was only required if these 
were not available, and utilization of local laboratories did not 
differ by region (US versus non-US).
Review of region-specific trial data may influence the reg-
ulatory approval process. The Food and Drug Administration 
is increasingly requesting pivotal clinical trials to include a 
certain proportion of patients enrolled from the United States. 
Regulatory bodies need to ensure representativeness and con-
sistency of efficacy and safety between the US subgroup and 
the overall trial sample. Subgroup analyses of the PLATO trial 
revealed that patients in North America assigned to ticagre-
lor experienced a higher rate of the primary end point of car-
diovascular death, MI, or stroke compared with clopidogrel; 
this treatment effect was disparate from that observed in other 
geographic regions.6 Three independent analytic teams have 
come to the conclusion that differences in aspirin mainte-
nance dose may partially explain these regional discrepancies 
in ticagrelor efficacy.6 This PLATO analysis has prompted the 
Food and Drug Administration to issue a black-box warning 
against the use of ticagrelor with aspirin doses exceeding 100 
mg/d. Thus, region-specific data from emerging cardiovascu-
lar trial programs may be important for regulatory approval, 
specific labeling, and restriction of use.
Despite the negative treatment-by-region interaction for 
the primary end points, it is still worthwhile to report and 
analyze regional data emerging from contemporary cardio-
vascular clinical trials. These trial programs present unique 
opportunities to describe evolving patient profiles, treatment 
practices, and cardiovascular disease burden in a well-mon-
itored global context. These region-specific data should be 
carefully interpreted to identify true geographic heterogeneity.
There are several limitations to this prespecified subgroup 
analysis. The overall trial was not powered to assess treatment 
effects by region. We did not adjust for multiple testing, and 
thus, heterogeneity across secondary end points may be due to 
chance alone from multiplicity of testing. The comparison of 
treatment effects in US and non-US subgroups was prespeci-
fied in this trial, and thus, we did not dissect the trial cohort 
further by specific region, country, or site. As such, we com-
bined regional data from all non-US sites, which may not be 
entirely uniform. Newer P2Y12 receptor antagonists, such as 
prasugrel and ticagrelor, were not used in this trial.
CHAMPION PHOENIX demonstrated reduced rates 
of 48-hour ischemic events with cangrelor compared with 
clopidogrel in patients undergoing PCI irrespective of region, 
without any excess in severe bleeding complications or trans-
fusions. Important differences in demographic and clinical 
characteristics, background therapies, and interventional fac-
tors were observed across the world. Despite this substantial 
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international variation in clinical profiles and indications for 
PCI, treatment effects on the primary safety and efficacy end 
points did not differ significantly by geographic region. Given 
increasing globalization of cardiovascular clinical trial pro-
grams, clinical trialists, regulatory authorities, and sponsors 
should continue to monitor and evaluate for potential regional 
variation in drug/device safety or efficacy. Standardization of 
end point assessment and selection of high-quality sites may 
minimize regional heterogeneity. In an era of decreasing US 
research engagement, robust US site participation in a global 
PCI trial was feasible with comparable regional results.
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